Video

Dr. Feldman on Durvalumab for Patients With Lung Cancer

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Durvalumab is a very exciting agent given the recently announced data that indicates an improvement in overall survival, especially in stage III patients with lung cancer.

This data shows that consolidation therapy after chemoradiation with durvalumab is a very promising combination. As a result, Feldman says he is looking forward to using durvalumab in his own practice.

Related Videos
Shaji Kumar, MD
Kevin Kalinsky, MD, MS
Guru P. Sonpavde, MD
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD